140 related articles for article (PubMed ID: 19122384)
1. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Tanaka N
Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
[TBL] [Abstract][Full Text] [Related]
2. [Oncolytic virotherapy for human solid tumors].
Fujiwara T
Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
[TBL] [Abstract][Full Text] [Related]
3. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
Fujiwara T; Tanaka N
Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
Fujiwara T; Urata Y; Tanaka N
Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
[TBL] [Abstract][Full Text] [Related]
5. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
Fujiwara T; Urata Y; Tanaka N
Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
[TBL] [Abstract][Full Text] [Related]
7. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
Kishimoto H; Urata Y; Tanaka N; Fujiwara T; Hoffman RM
Mol Cancer Ther; 2009 Nov; 8(11):3001-8. PubMed ID: 19887549
[TBL] [Abstract][Full Text] [Related]
8. Telomerase-specific replication-selective virotherapy for human cancer.
Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
Fujiwara T; Kagawa S; Tazawa H
Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
[TBL] [Abstract][Full Text] [Related]
10. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.
Kyo S; Takakura M; Fujiwara T; Inoue M
Cancer Sci; 2008 Aug; 99(8):1528-38. PubMed ID: 18754863
[TBL] [Abstract][Full Text] [Related]
11. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus.
Kishimoto H; Kojima T; Watanabe Y; Kagawa S; Fujiwara T; Uno F; Teraishi F; Kyo S; Mizuguchi H; Hashimoto Y; Urata Y; Tanaka N; Fujiwara T
Nat Med; 2006 Oct; 12(10):1213-9. PubMed ID: 17013385
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.
Fujiwara T; Shirakawa Y; Kagawa S
Expert Rev Anticancer Ther; 2011 Apr; 11(4):525-32. PubMed ID: 21504319
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
14. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene.
Umeoka T; Kawashima T; Kagawa S; Teraishi F; Taki M; Nishizaki M; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
Cancer Res; 2004 Sep; 64(17):6259-65. PubMed ID: 15342413
[TBL] [Abstract][Full Text] [Related]
15. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
16. In vivo imaging of human cancer with telomerase-specific replication-selective adenovirus.
Fujiwara T
Methods Mol Biol; 2012; 872():129-39. PubMed ID: 22700408
[TBL] [Abstract][Full Text] [Related]
17. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy.
Kojima T; Watanabe Y; Hashimoto Y; Kuroda S; Yamasaki Y; Yano S; Ouchi M; Tazawa H; Uno F; Kagawa S; Kyo S; Mizuguchi H; Urata Y; Tanaka N; Fujiwara T
Ann Surg; 2010 Jun; 251(6):1079-86. PubMed ID: 20485131
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M
Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088
[TBL] [Abstract][Full Text] [Related]
19. A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer.
Fujiwara T
Acta Med Okayama; 2011 Jun; 65(3):151-62. PubMed ID: 21709712
[TBL] [Abstract][Full Text] [Related]
20. Telomerase-specific virotheranostics for human head and neck cancer.
Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
